KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pfizer (PFE) EBIT (2016 - 2026)

Pfizer has reported EBIT over the past 18 years, most recently at -$6.7 billion for Q1 2026.

  • Quarterly EBIT fell 0.98% to -$6.7 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$17.7 billion through Mar 2026, down 83.68% year-over-year, with the annual reading at $20.7 billion for FY2025, 156.03% up from the prior year.
  • EBIT was -$6.7 billion for Q1 2026 at Pfizer, down from $4.2 billion in the prior quarter.
  • Over five years, EBIT peaked at $13.0 billion in Q3 2022 and troughed at -$13.8 billion in Q4 2023.
  • The 5-year median for EBIT is -$6.6 billion (2025), against an average of -$2.2 billion.
  • Year-over-year, EBIT soared 177.08% in 2024 and then plummeted 397.16% in 2025.
  • A 5-year view of EBIT shows it stood at $10.3 billion in 2022, then crashed by 227.15% to -$13.1 billion in 2023, then grew by 16.28% to -$11.0 billion in 2024, then skyrocketed by 137.82% to $4.2 billion in 2025, then tumbled by 261.62% to -$6.7 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's EBIT are -$6.7 billion (Q1 2026), $4.2 billion (Q4 2025), and -$7.8 billion (Q3 2025).